| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 4, 2002
Accepted on April 16, 2003
1 Laboratory of Endocrine Cell Biology, National Research Laboratory Program, Department of Internal Medicine; Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea; Friedrich Miescher Institute, Maulbeerstrasse 66, Basel CH-4058, Switzerland
* To whom correspondence should be addressed. E-mail: minhos{at}cnu.ac.kr.
Thyroid cancers are a leading cause of death due to endocrine malignancies. RET/PTC gene rearrangements are the most frequent genetic alterations identified in papillary thyroid carcinoma. Although the oncogenic potential of RET/PTC is related to intrinsic tyrosine kinase activity, the substrates for this enzyme are yet to be identified. In this report, we show that PDK1, a pivotal serine/threonine kinase in growth factor signaling pathways, is a target of RET/PTC. RET/PTC and PDK1 co-localize in the cytoplasm. RET/PTC phosphorylates a specific tyrosine (Y9) residue located in the N-terminal region of PDK1. Y9 phosphorylation of PDK1 by RET/PTC requires an intact catalytic kinase domain. The short (iso 9) and long forms (iso 51) of the RET/PTC kinases (RET/PTC1 and RET/PTC3) induce Y9 phosphorylation of PDK1. Moreover, Y9 phosphorylation of PDK1 by RET/PTC does not require PI3K or Src activity. RET/PTC-induced phosphorylation of the Y9 residue results in increased PDK1 activity, decrease of cellular p53 levels and repression of p53-dependent transactivation. In conclusion, RET/PTC-induced tyrosine phosphorylation of PDK1 may be one of the mechanisms through which it acts as an oncogenic tyrosine kinase in thyroid carcinogenesis.
This article has been cited by other articles:
![]() |
K. Block, A. Eid, K. K. Griendling, D.-Y. Lee, Y. Wittrant, and Y. Gorin Nox4 NAD(P)H Oxidase Mediates Src-dependent Tyrosine Phosphorylation of PDK-1 in Response to Angiotensin II: ROLE IN MESANGIAL CELL HYPERTROPHY AND FIBRONECTIN EXPRESSION J. Biol. Chem., August 29, 2008; 283(35): 24061 - 24076. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-J. Yang, S. Shin, L. Piao, E. Shin, Y. Li, K. A. Park, H. S. Byun, M. Won, J. Hong, G. R. Kweon, et al. Regulation of 3-Phosphoinositide-dependent Protein Kinase-1 (PDK1) by Src Involves Tyrosine Phosphorylation of PDK1 and Src Homology 2 Domain Binding J. Biol. Chem., January 18, 2008; 283(3): 1480 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Kim, H. K. Chung, K. C. Park, J. H. Hwang, Y. S. Jo, J. Chung, D. V. Kalvakolanu, N. Resta, and M. Shong Tumor Suppressor LKB1 Inhibits Activation of Signal Transducer and Activator of Transcription 3 (STAT3) by Thyroid Oncogenic Tyrosine Kinase Rearranged in Transformation (RET)/Papillary Thyroid Carcinoma (PTC) Mol. Endocrinol., December 1, 2007; 21(12): 3039 - 3049. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Barragan, M. de Frias, D. Iglesias-Serret, C. Campas, E. Castano, A. F. Santidrian, L. Coll-Mulet, A. M. Cosialls, A. Domingo, G. Pons, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta} J. Leukoc. Biol., December 1, 2006; 80(6): 1473 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, et al. An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4070 - 4076. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Seki, N. Irie, K. Nakamura, H. Sakaue, W. Ogawa, M. Kasuga, H. Yamamoto, S. Ohmori, N. Saito, and N. Sakai Fused protein of deltaPKC activation loop and PDK1-interacting fragment (deltaAL-PIF) functions as a pseudosubstrate and an inhibitory molecule for PDK1 when expressed in cells. Genes Cells, September 1, 2006; 11(9): 1051 - 1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Jung, D. W. Kim, Y. S. Jo, H. K. Chung, J. H. Song, J. S. Park, K. C. Park, S. H. Park, J. H. Hwang, K.-W. Jo, et al. Regulation of Protein Kinase B Tyrosine Phosphorylation by Thyroid-Specific Oncogenic RET/PTC Kinases Mol. Endocrinol., November 1, 2005; 19(11): 2748 - 2759. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wu, E. Mambo, Z. Guo, S. Hu, X. Huang, S. M. Gollin, B. Trink, P. W. Ladenson, D. Sidransky, and M. Xing Uncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4688 - 4693. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Park, K.-H. Song, H. K. Chung, H. Kim, D. W. Kim, J. H. Song, E. S. Hwang, H. S. Jung, S.-H. Park, I. Bae, et al. CR6-Interacting Factor 1 Interacts with Orphan Nuclear Receptor Nur77 and Inhibits Its Transactivation Mol. Endocrinol., January 1, 2005; 19(1): 12 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Seo, Y. Ahn, S.-R. Lee, C. Y. Yeo, and K. C. Hur The Major Target of the Endogenously Generated Reactive Oxygen Species in Response to Insulin Stimulation Is Phosphatase and Tensin Homolog and Not Phosphoinositide-3 Kinase (PI-3 Kinase) in the PI-3 Kinase/Akt Pathway Mol. Biol. Cell, January 1, 2005; 16(1): 348 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Hwang, D. W. Kim, J. H. Hwang, H. S. Jung, J. M. Suh, Y. J. Park, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, et al. Regulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT1-Dependent Genes by RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinoma) Oncogenic Tyrosine Kinases Mol. Endocrinol., November 1, 2004; 18(11): 2672 - 2684. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |